Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 10/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306832 | 1.00 | CCR2 (0.44) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL3383512 | 0.90 | CCR2 (0.44) | CCR2NR1H2MMP2ANPEPCYP1A2 | |
| SCHEMBL3384307 | 0.90 | CCR2 (0.44) | CCR2NR1H2MMP2ANPEPCYP1A2 | |
| SCHEMBL2309467 | 0.89 | CCR2 (0.45) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL4303999 | 0.89 | ALDH1A1 (0.43) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL4304000 | 0.89 | ALDH1A1 (0.43) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL2363475 | 0.87 | CCR2 (0.42) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL2307831 | 0.86 | CCR2 (0.40) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL2307409 | 0.86 | CCR2 (0.40) | CCR2NR1H2NR1H3ALDH1A1MMP2 | |
| SCHEMBL29389706 | 0.86 | CCR2 (0.40) | CCR2NR1H2NR1H3ALDH1A1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039622-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-10-06 | — | — | US | disclosed |
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-09-29 | — | — | US | disclosed |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2011-09-15 | — | — | US | disclosed |
| EP-2350060-A2 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd (KR) | 2011-08-03 | — | — | EP | disclosed |
| US-7879852-B2 | such as (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide, used for the treatment of obesity, diabetes, inflammation and erectile dysfunction | LG LIFE SCIENCES LTD. (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCE LTD. (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20090298829-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2009-12-03 | — | — | US | disclosed |
| EP-2041120-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | CCR2 470/4885NR1H2 539/4885NR1H3 560/4885 |
| US-20090298829-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | CCR2 562/4885NR1H2 476/4885NR1H3 504/4885 |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | CCR2 470/4885NR1H2 539/4885NR1H3 560/4885 |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | CCR2 470/4885NR1H2 539/4885NR1H3 560/4885 |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | CCR2 470/4885NR1H2 539/4885NR1H3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.